Abstract: An engineered polypeptide includes at least two units, wherein each unit includes a polypeptide of SEQ ID NO: 4, a polypeptide of SEQ ID NO: 5, a polypeptide with 90% or greater homology to SEQ ID NO: 4, or a polypeptide with 90% or greater homology to SEQ ID NO: 5, wherein the engineered polypeptide does not comprise SEQ ID NO: 12 or SEQ ID NO: 13. Further described is a synthetic materials including the peptides. Also included are synthetic materials including polypeptide of any one of SEQ ID NOs: 9-32, a polypeptide with 90% or greater homology any one of SEQ ID NOs: 9-32, a polypeptide encoded by any one of SEQ ID NOs. 57-79, or a polypeptide with 90% or greater homology to a polypeptide encoded by any one of SEQ ID NOs. 57-79.

Abstract: In various embodiments, the present invention provides a method comprising: disposing upon a first substrate, a first coating; texturing the first coating with a stamp; treating the textured first coating to form a master mold; where the master mold contains a mirror image of the texture contained in the first coating; and transferring the texture from the master mold to a second substrate.

Abstract: In some aspects, the disclosure relates to compositions and methods for modulating (e.g., increasing and/or decreasing) bone mass in a subject. In some aspects, the disclosure provides isolated nucleic acids, and vectors such as rAAV vectors, configured to express transgenes that promote (e.g., increase) or inhibit (e.g., decrease) activity, differentiation, or function of certain types of bone cells, for example osteoblasts, osteoclasts, osteocytes, etc. In some embodiments, the isolated nucleic acids and vectors described by the disclosure are useful for treating disorders and conditions associated with increased bone mass (e.g., osteopetrosis) or decreased bone mass (e.g., osteoporosis).

Abstract: Aspects of the disclosure relate to compositions and methods for treating spinal muscular atrophy (SMA). The disclosure is based, in part, on isolated nucleic acids and vectors (e.g., viral vectors, such as rAAV vectors) encoding SMN1. In some embodiments, the expression of SMN 1 is driven by a native SMN 1 promoter or a variant thereof. In some embodiments, isolated nucleic acids and vectors of the disclosure have reduced toxicity and/or increased transgene expression relative to previously described SMN-encoding vectors.

Abstract: Gold compounds and pharmaceutically acceptable salts thereof are disclosed. Certain compounds and salts are active as antibacterial, antifungal, and/or anti-parasitic agents. The disclosure provides pharmaceutical compositions containing the gold compounds. Methods of using the gold compounds to treat bacterial infections are disclosed.

Abstract: The invention provides novel compounds, pharmaceutical compositions and methods of preparation and therapeutic use thereof. The invention also provides novel gel compositions comprising hyaluronic acid (HA) polymers that are crosslinked with appropriate reversible crosslinkers and encapsulation of therapeutics or other payloads in such gel composition and nanoparticles thereof. The invention also relates to targeted delivery of such gel compositions and nanoparticles to specific cell types in a controllable delivery and release. The invention additionally relates to methods of therapeutic use of such gel compositions and nanoparticles in treatment of various diseases and conditions. The invention further relates to methods of preparation of the gel compositions and nanoparticles disclosed herein.

Abstract: Methods for treating glaucoma and/or Fas ligand-dependent inflammatory conditions in a subject using soluble Fas ligand (sFasL) or a fragment thereof, which may be rAAV-mediated delivery of sFasL or a fragment thereof to a subject.

Abstract: A method of predicting neural activation and psychopathology, indicative of ADHD and mood and anxiety disorders in a subject, such as children, is disclosed. The method may be implemented via computer software on a tablet computer, laptop or desktop computer, an input device, such as touchscreen, keyboard or mouse, and a camera. The camera is positioned to capture the subject's face in the frame of the camera. A frustration-inducing activity, such as a game, to the subject, where the subject received positive or negative feedback based on the selections they make in a game. The subject's reactions to the feedback are captured and parsed by the software, to determine the subject's emotional reaction to feedback. Reactions such as eye gaze, head pose, and facial expression may be used. Over a number of trials of the game, a prediction may be made for the neural activation and psychopathology of the subject.

Abstract: A complex includes an amyloid peptide complexed with a cholinesterase inhibitor, an NMDA receptor antagonist, or a combination, of a cholinesterase inhibitor and an NMDA receptor antagonist, wherein the amyloid peptide comprises X1X2GAIIGX3X4 (SEQ ID NO: 2), wherein X1 and X4 are each independently YF or FY, and X2 and X3 are each 1 amino acid long, and are each independently T, N, S, or Q; or X2 and X3 are each 2 amino acid long and X2 is (Y or F)T, (Y or F)N, (Y or F)S or (Y or F)Q, and X3 is T(Y or F), N(Y or F), S(Y or F) or Q(Y or F), wherein the amyloid peptide self-assembles into amyloid fibrils, and wherein the peptide has a total length of 11-13 amino acids.

Abstract: In some aspects, the disclosure relates methods and compositions for genetic engineering of cells (e.g., bacterial cells, etc.). The disclosure is based, in part, on a combination of genetic recombination systems (e.g., a “targeting oligonucleotide” and a “payload plasmid) that enable high-throughput chromosomal engineering and do not involve the preparation of double-stranded DNA (dsDNA) recombination substrates. In some aspects, the disclosure provides engineered bacterial cells comprising a targeting oligonucleotide and a payload plasmid.

Abstract: Therapeutic oligonucleotides comprising pharmacokinetic (PK)-modifying anchors are provided. Methods for treating diseases or disorders comprising administering to a subject a therapeutic oligonucleotide comprising one or more PK-modifying anchors are provided.

Abstract: A pre-loaded stent graft delivery device and stent graft, the stent graft delivery device. The stent graft has at least one fenestration or side arm and the fenestration is preloaded with an indwelling guide wire. Indwelling access sheaths are provided within auxiliary lumens of a pusher catheter and dilators are preloaded into the access sheaths along with the indwelling guide wire. The auxiliary lumens have an oblong cross-section. A handle assembly at a distal end of the guide wire catheter. The handle includes a multiport manifold with access ports to the auxiliary lumens in the pusher catheter. Upon deployment of the stent graft, the indwelling guide wire can be used to facilitate catheterization of a side branch or target vessel through the fenestration or be used to stabilize the access sheath during catheterization, advancement of the access sheath into the target vessel and deployment of a stent therein.

Abstract: Aspects of the disclosure relate to compositions and methods for treating spinal muscular atrophy (SMA). The disclosure is based, in part, on isolated nucleic acids and vectors (e.g., viral vectors, such as rAAV vectors) encoding SMN1. In some embodiments, the expression of SMN1 is driven by a native SMN1 promoter or a variant thereof. In some embodiments, isolated nucleic acids and vectors of the disclosure have reduced toxicity and/or increased transgene expression relative to previously described SMN-encoding vectors.

Abstract: Various examples disclosed relate to a method of manufacturing a mechanically stabilized material that includes a nanostructure. The method includes providing a curable material disposed on a substrate. The curable material includes inorganic nanoparticles. The method further includes exposing the curable material and the substrate to pulsed electromagnetic radiation to form the mechanically stabilized material.

Abstract: Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.

Abstract: An energy absorbing structure and method of making thereof is disclosed. The energy absorbing structure comprises an energy absorbing lattice structure having an irregular, but not random, lattice pattern. The irregular lattice pattern of the energy absorbing lattice structure may be a Voronoi cell pattern, which may be derived from a bovid skull horncore morphology. Other lattice patterns may be used, such as two-dimensional tessellations forming a distribution of asymmetric polygons or three-dimensional tessellations to form a distribution of asymmetric polyhedral shapes. The energy absorbing structure may further comprise one or more substrates to one or more sides of the energy absorbing lattice structure. The energy absorbing structure may be formed through additive manufacturing and has a variety of applications including, but not limited to, helmet liners, protective gear, shoe soles, packaging material, vehicle panels, or phone cases.

Abstract: The invention provides anti-polymeric IgA (plgA) antibodies and methods of using the same.

Abstract: The present disclosure relates to the field of rAAV delivery of transgenes. In some aspects, the disclosure relates to RNAi. Provided herein are recombinant adeno-associated virus (rAAV) vectors comprising modified ITRs. In some embodiments, the modified ITRs comprise a sequence encoding a shRNA, miRNA, or AmiRNA.

Abstract: In some aspects, the disclosure provides recombinant AAV and nucleic acid constructs having novel inverted terminal repeats (ITRs), cap, and/or rep genes. In some aspects, the disclosure relates to gene transfer methods using rAAVs described herein.

Abstract: Translation modulating agents that modulate expression of one or more translation start sites for expanded repeat (e.g., DPR) protein synthesis are provided. Compositions and methods for treating translation start sites for expanded repeat (e.g., DPR) protein synthesis-associated disorders are also provided.